• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Respiratory/Inflammation

The following trials provide information to treat various types of respiratory and inflammatory diseases, both for ongoing and completed clinical trials.  For more information on both of these therapy areas please click here.

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.

  • Expand All
  • Collapse All
  • Pages
  • Previous
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • Next
  • collapse AZD9164 Single Ascending Dose Study in Healthy Male Subjects
  • collapse A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®
  • collapse Factors Determining Quality of Life Related to Respiratory Status According to Gender of Chronic Obstructive Pulmonary Disease (COPD) Patients
  • collapse A 6 months NIS to evaluate the use of rescue medication and quality of life in adult asthmatic subjects treated with Symbicort SMART 1-2 inhalations b.i.d. as maintenance therapy plus additional inhalations as-needed, compared to patients treated with a free combination of an inhaled glucocorticosteroid and an inhaled long acting ß2-agonist plus as needed inhalations of a short acting ß2 agonist.
  • collapse A randomised, placebo-controlled, double-blind (double-dummy technique),crossover, multi-centre study, to evaluate onset of effect in patients with Chronic Obstructive Pulmonary Disease (COPD) treated with formoterolTurbuhaler 9 μg, compared with Serevent Diskus 50 μg.
  • collapse To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol pMDI a Single Blind Study
  • collapse A descriptive study to explore certain characteristics of patients at risk for COPD in a primary care setting.
  • collapse A follow-up programme for patients using Symbicort Turbuhaler maintenance and reliever therapy in normal clinical practice.
  • collapse Symbicort SMART Satisfaction from Patient Perspective 2009
  • collapse A Comparison of SYMBICORT pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.
  • Pages
  • Previous
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013